Endexx Corporation (EDXC), which is a progressive lifestyle company that primarily deals with the science intersection, matters of compliance, and development of new, creative nutritional products and food-centered on phytonutrients, has today announced the inauguration of the company’s latest product line.
The new product is a CBD-line which are designed for pets; the Phyto-Drops. The new line of product meant to complement the recently-introduced soft chews PhytoBites. The substance, which first came out in 2016, is aimed at building a robust catalog of pet products. The Chairman and Chief Executive Officer at Endexx, Todd Davis said:
“We proceeded to develop, research, and build new substances since R&D firmly steeped in our company's DNA. Our products are designed through all-natural ingredients. They are inherently laced with natural oils and deprived of sugar. We are happy to release this new product to the broader market; in the meantime, our company’s pet division is proceeding with its lead in producing items that are in high demand.”
Sugarless, All-Natural Ingredients
“During this great change in consumer preferences and buying habits occasioned by the current pandemic, our product line will, for the time being, be available online; those wishing to access the products can visit either our website or the wholesale network.”
“Generally, CBD products that have no sugar and which have all-natural ingredients are known to guarantee the purity and quality of products for their dogs, cats, as well as their families. Our range of products does a lot to enhance the customer’s life-quality, as well as that of pets.’ We, however, remain focused on innovation that revolves around consumers. The launch of this product reflects our commitment to customers.”
Significantly, the new Phyto-Drops CBD product, which is aimed for pets, can be bought in 10 ml and 30 ml formulas. They are available on the popular e-commerce website known as “Unlimited.” Further, CBD Unlimited oils are devoid of additives; during production, each product is tested in the lab to make sure the items are of high-quality.
Individuals can learn more about the products on the company's website.
Facts on CBD UnLimited and Endexx Corporation
Usually, Endexx Corporation develops and distributes, CBD products that are manufactured from hemp or cannabis Sativa plant. These products are typically all-natural and contain a tiny quantity of THC, less than 0.01%. The company mainly operates through the CBD Unlimited division.
The products from this agency include topicals, capsules, pet products, and oil. All of these have the shared goal of pain relief and therapeutic effects for both pets and humans. Mostly, Phyto-Bites are soft chews CBD that are meant to be used by animals. They are developed to reinforce the reduction of anxiety that comes about due to separation, inflammation, or pain.
Further, these products are derived from in-depth science, involving decades of clinical research both in the laboratory and the field. They are also aimed at protecting the accuracy in delivery and dosage with regards to absorption for each serving of the substance.
To provide the necessary conformity with state and federal mandates, the company has adopted a platform known as the “Gorilla-Tek” into its essential business fabric. This platform is the leading standardized software and hardware agnostic solution that works by tracking high-shrink-regulated and high-risk, restricted products that are maintained under local, state, and federal compliance.
The said platform deals with matters of asset protection, compliance, inventory management, and end- of- sale integration technology. Premised on specific principles derived from the pharmacology industry, the “Gorilla-Tek” platform, which is highly integrated, is also quite efficient since it offers a detailed accounting and product regime. Moreover, “Gorilla Tek” generally enhances productivity, reducing costs in good time for the customers.
Notice of Safe Harbor
The press release above is likely to contain some forward-seeking statements under the context of the 1995 Private Securities Litigation. These include comments that relate to financial results and procedures for future activities of development; in this sense, they are primarily prospective. Such statements generally include all non- historical fact statements about belief, intent, or present company expectations or the intents of its officers and directors.
Investors are warned that such statements do not guarantee future performance since they involve uncertainties and risks. Usually, most of these factors are beyond the control of the company. The results may significantly differ in a material way from what is indicated in the statements.
Other factors that could cause the results to differ substantially are uncertainties and risks that come with company finances and businesses, including the ability to manage competition, growth, global economic factors and other issues which were discussed at length in the periodic filings of the company that are forwarded to the Securities and Exchange Commission.
Thus, from this deduction, the company has no obligation to update such forward-looking documents.